Antares Pharma to Report Third Quarter 2017 Financial and Operating Results and Host Webcast and Conference Call
October 31 2017 - 7:00AM
Antares Pharma, Inc. (NASDAQ:ATRS) today announced it will release
its third quarter 2017 financial results and recent operating
progress before the market opens on Tuesday, November 7,
2017. Management will host a webcast and conference call at
8:30 a.m. ET (Eastern Time) on November 7, 2017 to discuss the
results.
Interested parties may participate in the
conference call by dialing 1-866-564-2842 (U.S.) or 1-323-794-2094
(international) and entering access code 8463517. We
encourage interested parties to dial into the conference call at
least 10 minutes prior to the scheduled start time. A replay
of the conference call will be available from 11:30 a.m. ET on
Tuesday, November 7, 2017, through 11:30 a.m. ET on Thursday,
December 7, 2017 by dialing 1-888-203-1112 (U.S.) or 1-719-457-0820
(international), and entering the access code 8463517. An
audio webcast and archive of the conference call will also be
available under the investor information section of the Antares
Website at www.antarespharma.com.
About Antares Pharma
Antares Pharma focuses on self-administered
parenteral pharmaceutical products. The Company’s product, OTREXUP®
(methotrexate) injection for subcutaneous use, is approved in the
U.S. for the treatment of adults with severe active rheumatoid
arthritis, children with active polyarticular juvenile idiopathic
arthritis and adults with severe recalcitrant psoriasis. The
Company’s product Sumatriptan Injection USP, is approved in the
U.S. for the acute treatment of migraine and cluster headache and
is distributed by Teva Pharmaceutical Industries, Ltd. (Teva).
Antares Pharma is also developing an investigational new drug,
XYOSTED™, for testosterone replacement therapy. The Company's
technology platforms include VIBEX® disposable auto injectors and
disposable multi-use pen injectors. Antares Pharma has license,
development and supply agreements with Teva that include VIBEX®
epinephrine, exenatide multi-dose pen, and teriparatide multi-dose
pen. The Company is also working with AMAG Pharmaceuticals on a
subcutaneous method for administering Makena, a progesterone
product indicated for use in lowering the risk of pre-term
birth. For more information, visit www.antarespharma.com.
SAFE HARBOR STATEMENT UNDER THE PRIVATE
SECURITIES LITIGATION REFORM ACT OF 1995
This press release contains
forward-looking statements within the meaning of the safe harbor
provisions of the Private Securities Litigation Reform Act of
1995. Forward-looking statements are subject to certain risks
and uncertainties that can cause actual results to differ
materially from those described. Factors that may cause such
differences include, but are not limited to: the Company’s ability
to adequately and timely respond to the deficiencies in the
XYOSTED™ CRL issued by the FDA, whether any such response will be
accepted by the FDA, the Company’s ability and
timing to resubmit the NDA for XYOSTED™, and FDA acceptance of the
resubmitted NDA and any approval of the Company’s NDA for
XYOSTED™, successful completion of the
transaction with Ferring International Center, S.A. and
satisfaction of the various conditions in the Ferring asset
purchase agreement and payment of the full purchase price, FDA
approval of the sNDA submitted by AMAG Pharmaceuticals for an auto
injector for Makena and future market acceptance and revenue of the
same; the outcome of the pending patent litigation between Teva
Pharmaceutical Industries, Ltd. (Teva) and Eli Lilly and the
Company regarding the Teriparatide multi-dose pen; FDA action with
respect to Teva’s Abbreviated New Drug Application (“ANDA”) for the
Teriparatide multi-dose pen and the timing and approval, if any, by
the FDA of the same; Teva’s expectations about timing and approval
of the VIBEX® epinephrine pen ANDA by the FDA and potential product
launch of the same, the therapeutic equivalence rating thereof, and
any future revenue from the same; Teva’s ability to successfully
commercialize VIBEX® Sumatriptan Injection USP and the amount of
revenue from the same; FDA action with respect to Teva’s ANDA filed
for the Exenatide pen and future revenue from the same; continued
growth of prescriptions and sales of OTREXUP®; the timing and
results of research projects, clinical trials, and product
candidates in development; actions by the FDA or other regulatory
agencies with the respect to the Company’s products or product
candidates of its partners; continued growth in product,
development, licensing and royalty revenue; the Company’s ability
to obtain financial and other resources for its research,
development, clinical, and commercial activities and other
statements regarding matters that are not historical facts, and
involve predictions. These statements involve known and unknown
risks, uncertainties and other factors that may cause actual
results, performance, achievements or prospects to be materially
different from any future results, performance, achievements or
prospects expressed in or implied by such forward-looking
statements. In some cases you can identify forward-looking
statements by terminology such as ''may'', ''will'', ''should'',
''would'', ''expect'', ''intend'', ''plan'', ''anticipate'',
''believe'', ''estimate'', ''predict'', ''potential'', ''seem'',
''seek'', ''future'', ''continue'', or ''appear'' or the negative
of these terms or similar expressions, although not all
forward-looking statements contain these identifying words.
Additional information concerning these and other factors that may
cause actual results to differ materially from those anticipated in
the forward-looking statements is contained in the "Risk Factors"
section of the Company's Annual Report on Form 10-K for the year
ended December 31, 2016, and in the Company's other periodic
reports and filings with the Securities and Exchange
Commission. The Company cautions investors not to place undue
reliance on the forward-looking statements contained in this press
release. All forward-looking statements are based on information
currently available to the Company on the date hereof, and the
Company undertakes no obligation to revise or update these
forward-looking statements to reflect events or circumstances after
the date of this press release, except as required by
law.
Contacts:Jack HowarthVice President, Corporate
Affairs609-359-3016jhowarth@antarespharma.com
Antares Pharma (NASDAQ:ATRS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Antares Pharma (NASDAQ:ATRS)
Historical Stock Chart
From Jul 2023 to Jul 2024